FDA slaps hold on Zolgensma trials as animal data raises saf...

Novartis takes $80M punt on early-stage NASH drug from Plian...

Zolgensma hits the ground running, says Novartis

Sandoz says ‘no’ to Pear Therapeutics’ digital apps, handing...

Novartis' new eye drug undercuts Bayer's rival with fewer in...

The FDA has approved Novartis’s new eye drug brolucizumab for wet age-related macular degeneration, which will match Bayer’s rival Eylea on price per dose but reduce costs with a less frequ

Novartis taps Microsoft’s AI expertise for drug development

Novartis has forged an alliance with Microsoft that will apply artificial intelligence and machine-learning to the discovery